March, 2024
March 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Naveen Pemmaraju: Brand new paper CPX351 for patients with HR MDS and CMML s/p HMA
Nov 15, 2023, 17:56

Naveen Pemmaraju: Brand new paper CPX351 for patients with HR MDS and CMML s/p HMA

Quoting Naveen Pemmaraju on X/Twitter:

“Brand new paper alert from our group led by Dr. Guillermo Montalban-Bravo and Garcia-Manero: CPX351 for patients with HR MDS and CMML s/p HMA.”

For the article click here.
Source: Naveen Pemmaraju/Twitter

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML. He has been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020, which is one of the world’s most active BPDCN research programs. Dr. Pemmaraju is the recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. He is a well-known social media influencer and advocate.